Rose Brannon, A. http://orcid.org/0000-0003-4610-0149
Jayakumaran, Gowtham
Diosdado, Monica http://orcid.org/0000-0002-3475-9985
Patel, Juber
Razumova, Anna
Hu, Yu
Meng, Fanli
Haque, Mohammad
Sadowska, Justyna
Murphy, Brian J.
Baldi, Tessara
Johnson, Ian http://orcid.org/0000-0002-0353-1195
Ptashkin, Ryan
Hasan, Maysun http://orcid.org/0000-0002-6496-4752
Srinivasan, Preethi
Rema, Anoop Balakrishnan http://orcid.org/0000-0001-6104-5665
Rijo, Ivelise
Agarunov, Aaron
Won, Helen
Perera, Dilmi
Brown, David N.
Samoila, Aliaksandra
Jing, Xiaohong
Gedvilaite, Erika http://orcid.org/0000-0003-1749-0045
Yang, Julie L. http://orcid.org/0000-0003-4747-6391
Stephens, Dennis P.
Dix, Jenna-Marie http://orcid.org/0000-0001-8822-4049
DeGroat, Nicole
Nafa, Khedoudja
Syed, Aijazuddin
Li, Alan
Lebow, Emily S.
Bowman, Anita S. http://orcid.org/0000-0002-8651-5317
Ferguson, Donna C.
Liu, Ying
Mata, Douglas A.
Sharma, Rohit
Yang, Soo-Ryum
Bale, Tejus
Benhamida, Jamal K. http://orcid.org/0000-0001-5542-9857
Chang, Jason C.
Dogan, Snjezana
Hameed, Meera R.
Hechtman, Jaclyn F.
Moung, Christine
Ross, Dara S.
Vakiani, Efsevia
Vanderbilt, Chad M. http://orcid.org/0000-0002-8114-0237
Yao, JinJuan
Razavi, Pedram http://orcid.org/0000-0003-4236-0576
Smyth, Lillian M. http://orcid.org/0000-0002-0986-9285
Chandarlapaty, Sarat http://orcid.org/0000-0003-4532-8053
Iyer, Gopa http://orcid.org/0000-0002-5093-6099
Abida, Wassim
Harding, James J.
Krantz, Benjamin
O’Reilly, Eileen http://orcid.org/0000-0002-8076-9199
Yu, Helena A.
Li, Bob T. http://orcid.org/0000-0001-6661-8733
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Diaz, Luis http://orcid.org/0000-0002-7079-8914
Solit, David B. http://orcid.org/0000-0002-6614-802X
Arcila, Maria E.
Ladanyi, Marc
Loomis, Brian http://orcid.org/0000-0002-1863-1199
Tsui, Dana
Berger, Michael F. http://orcid.org/0000-0003-3882-5000
Zehir, Ahmet http://orcid.org/0000-0001-5406-4104
Benayed, Ryma http://orcid.org/0000-0002-3754-0321
Article History
Received: 2 December 2020
Accepted: 26 May 2021
First Online: 18 June 2021
Competing interests
: D.B.S. has served as a consultant for/received honoraria from Loxo Oncology, Lilly Oncology, Pfizer, QED Therapeutics, Vivideon Therapeutics and Illumina. M.E.A. received speaker and consulting fees from Invivoscribe, Biocartis, AstraZeneca,Bristol-Myers Squibb, Clinical Care Options, PVI Peerview, Janssen Global Services, LLC, Physicians’ Education Resource, LLC. M.L. has received advisory board compensation from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Takeda, and Bayer, and research support from LOXO Oncology and Helsinn Healthcare. <b>A.</b>R.B. has stock ownership in Johnson & Johnson. <b>S.R.Y</b> has received consulting fees from Invitae. M.F.B. has received consulting fees from Roche and grant support from Illumina and Grail. M.F.B., D.T., P.S., J.P., B.H.L., M.H., and F.M. are co-inventors on a provisional patent application for systems and methods for detecting cancer via cfDNA screening. A.Z. received speaking fees from Illumina. B.H.L. receives royalties from BioLegend for development of products related to CITE-seq. J.H. has received research funding from Bayer, Eli Lilly, and Boehringer Ingelheim; and honoraria or consulting fees from Axiom Healthcare Stetegies, WebMD, Illumina, and Cor2Ed. K.N. has received honoraria from Biocartis. S.C. has received consulting fees from Sermonix, Paige.ai, Novartis, and Lilly. J.J.H. has received consulting fees from Bristol Myers Squibb, Exelexis, Eisai, Merck, ImVax, CytomX, and Eli Lilly and research support from Bristol Myers Squibb, the Wien Initiative in Liver Cancer Research, and the Society of MSKCC. H.Y. has consulted for AstraZeneca, Blueprint Medicine, Janssen Oncology and Daiichi. Her institution has received research funding for clinical trials from AstraZeneca, Daiichi, Pfizer, Novartis, Cullinan Oncology, Lilly. W.A. has received research funding from AstraZeneca, Zenith Epigenetics, Clovis Oncology, GlaxoSmithKline; and honoraria or consulting fees from CARET, Clovis Oncology, Janssen, MORE Health, ORIC Pharmaceuticals, Daiichi Sankyo. L.M.S. is an employee of Loxo Oncology at Lilly. L.M.S. has consulted for Novartis, Pfizer, AstraZeneca and Roche Genentech; received research funding from AstraZeneca, Puma Biotechnology and Roche Genentech; travel or accommodations expenses from AstraZeneca, Pfizer, Puma Biotechnology and Roche Genentech; honoraria from Pfizer and AstraZeneca. D.T. has received research support from ThermoFisher Scientific, EPIC Sciences, speaking honoraria and travel support from Nanodigmbio, Cowen, BoA Merrill Lynch, D.T. and L.D. are co-inventors on a provisional patent application for systems and methods for distinguishing pathological mutations from clonal hematopoietic mutations in plasma cell-free DNA by fragment size analysis. R.B. has received a grant and travel credit from ArcherDx, honoraria for advisory board participation from Loxo oncology and speaking fees from Illumina. B.T.L. has served as an uncompensated advisor and consultant to Amgen, Genentech, Boehringer Ingelheim, Lilly, AstraZeneca, Daiichi Sankyo, and has received consulting fees from Guardant Health and Hengrui Therapeutics. He has received research grants to his institution from Amgen, Genentech, AstraZeneca, Daiichi Sankyo, Lilly, Illumina, GRAIL, Guardant Health, Hengrui Therapeutics, MORE Health and Bolt Biotherapeutics. He has received academic travel support from Resolution Bioscience, MORE Health, and Jiangsu Hengrui Medicine. He is an inventor on two institutional patents at MSK (US62/685,057, US62/514,661) and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. B.T.L. is supported by the Memorial Sloan Kettering Cancer Center Support Grant P30 CA008748 from the National Institutes of Health. C.M.V. discloses relationships and financial interests with the following: DocDoc Pte. Ltd. (Provision of Services), Paige.AI, Inc (Ownership/Equity Interests; Provision of Services). E.O.: Research Funding to MSK: Genentech/Roche, Celgene/BMS, BioNTech, BioAtla, AstraZeneca, Arcus, Elicio, Parker Institute, AstraZeneca, Pertzye. Consulting Role: Cytomx Therapeutics (DSMB), Rafael Therapeutics (DSMB), Sobi, Silenseed, Tyme, Seagen, Molecular Templates, Boehringer Ingelheim, BioNTech, Ipsen, Polaris, Merck, IDEAYA, Cend, AstraZeneca, Noxxon, BioSapien, Bayer (spouse), Genentech-Roche (spouse), Celgene-BMS (spouse), Eisai (spouse). P.R. received institutional grant/funding from Grail, Illumina, Novartis, Epic Sciences, ArcherDx and Consultation/Ad board/Honoraria from Novartis, Foundation Medicine, AstraZeneca, Epic Sciences, Inivata, Natera, and Tempus. C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, Epizyme, Genentech/Roche, Ipsen, Jazz, Lilly, and Syros. CMR serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. G.I. reports consulting/advisory role: Bayer, Janssen, Mirati Therapeutics, Basilea Pharmaceutical and Research Funding: Mirati Therapeutics, Novartis, Seagen, Inc, Bayer, Janssen, Debiopharm. Honoraria: The Lynx Group, DAVA Oncology. G.J., M.D., A.R., Y.H., M.H., J.S., B.J.M., T.B., I.J., R.P., A.B.R., I.R., A.A., H.W., D.P., D.N.B., A.S., X.J., E.G., J.L.Y., D.P.S., J.D., N.D., A.S., A.L., E.S.L., A.S.B., D.C.F., Y.L., D.A.M., R.S., T.B., J.K.B., J.C.C., S.D., M.H., C.M., D.S.R., V.E., J.Y., and B.K. have no relevant competing interests to declare.